Gabapentin Tablet
Product Images NDC 68071-2214

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2214). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2214 9)

Label for Gabapentin 800 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a package containing 90 tablets. Each film-coated tablet contains 800 mg of Gabapentin. The label includes product identification numbers, a storage temperature recommendation (59-86°F), and warnings to keep out of reach of children. Manufacturer details and lot, expiration, and serial numbers are also present.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over a 7-week period for placebo and gabapentin doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks from baseline through 7 weeks, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both gabapentin groups show a decline in mean pain scores over time, while the placebo group shows a relatively steady mean pain score.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at different dosages in two studies. The vertical axis shows response percentages from 0% to 100%. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg; Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is noted with p values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula table showing the calculation for creatinine clearance (CLCr) as a function of age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients. This type of formula is commonly used in clinical pharmacokinetics to estimate kidney function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring attached to a side chain with an amino group and a carboxyl group.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot chart depicting the percentage difference on the y-axis versus daily dose in mg on the x-axis, with data points from three studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c.' The chart shows values for daily doses of 600, 900, 1200, and 1800 mg with corresponding percentage differences for each study, illustrating comparative differences across doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.